fotemustine nitrosourea alkylating agent used treatment metastatic melanoma available europe approved united states shown fotemustine produces improved response rates increase survival dacarbazine treatment disseminated cutaneous melanoma median survival months fotemustine versus months dtic also toxicity prevalence fotemustine arm main toxicity grade neutropenia fotemustine v dtic thrombocytopenia v respectively antineoplastic immunomodulatory drug article stub help wikipedia expanding httpsenwikipediaorgwikifotemustine